Hypoperfusion of brain parenchyma is associated with the severity of chronic cerebrospinal venous insufficiency in patients with multiple sclerosis: a cross-sectional preliminary report by Zamboni, Paolo et al.
Hypoperfusion of brain parenchyma is associated with the
severity of chronic cerebrospinal venous insufficiency in
patients with multiple sclerosis: a cross-sectional
preliminary report
Zamboni et al.
Zamboni et al. BMC Medicine 2011, 9:22
http://www.biomedcentral.com/1741-7015/9/22 (7 March 2011)RESEARCH ARTICLE Open Access
Hypoperfusion of brain parenchyma is associated
with the severity of chronic cerebrospinal venous
insufficiency in patients with multiple sclerosis: a
cross-sectional preliminary report
Paolo Zamboni
1*, Erica Menegatti
1, Bianca Weinstock-Guttman
2, Michael G Dwyer
3, Claudiu V Schirda
3,
Anna M Malagoni
1, David Hojnacki
2, Cheryl Kennedy
3, Ellen Carl
3, Niels Bergsland
3, Christopher Magnano
3,
Ilaria Bartolomei
1, Fabrizio Salvi
1, Robert Zivadinov
2,3
Abstract
Background: Several studies have reported hypoperfusion of the brain parenchyma in multiple sclerosis (MS)
patients. We hypothesized a possible relationship between abnormal perfusion in MS and hampered venous
outflow at the extracranial level, a condition possibly associated with MS and known as chronic cerebrospinal
venous insufficiency (CCSVI).
Methods: We investigated the relationship between CCSVI and cerebral perfusion in 16 CCSVI MS patients and 8
age- and sex-matched healthy controls. Subjects were scanned in a 3-T scanner using dynamic susceptibility,
contrast-enhanced, perfusion-weighted imaging. Cerebral blood flow (CBF), cerebral blood volume (CBV) and mean
transit time (MTT) were measured in the gray matter (GM), white matter (WM) and the subcortical GM (SGM). The
severity of CCSVI was assessed according to the venous hemodynamic insufficiency severity score (VHISS) on the
basis of the number of venous segments exhibiting flow abnormalities.
Results: There was a significant association between increased VHISS and decreased CBF in the majority of
examined regions of the brain parenchyma in MS patients. The most robust correlations were observed for GM
and WM (r = -0.70 to -0.71, P < 0.002 and P corrected = 0.022), and for the putamen, thalamus, pulvinar nucleus of
thalamus, globus pallidus and hippocampus (r = -0.59 to -0.71, P < 0.01 and P corrected < 0.05). No results for
correlation between VHISS and CBV or MTT survived multiple comparison correction.
Conclusions: This pilot study is the first to report a significant relationship between the severity of CCSVI and
hypoperfusion in the brain parenchyma. These preliminary findings should be confirmed in a larger cohort of MS
patients to ensure that they generalize to the MS population as a whole. Reduced perfusion could contribute to
the known mechanisms of virtual hypoxia in degenerated axons.
Background
Chronic cerebrospinal venous insufficiency (CCSVI) is a
vascular condition described in multiple sclerosis (MS)
patients and characterized by multiple intraluminal ste-
nosing malformations of the principal pathways of extra-
cranial venous drainage, particularly in the internal
jugular veins (IJVs) and the azygous vein (AZY), that
restrict the normal outflow of blood from the brain [1,2].
The concept of CCSVI in MS patients and its possible
implications on MS pathogenesis and treatment options
has raised significant interest in both the patient and
medical communities. Surgical interventions are under
consideration in patients with MS and it is important to
understand the relevance of CCSVI in the context of
well-established hemodynamic brain MRI outcomes.
Several studies have reported hypoperfusion of the brain
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onset [3,4]. Changes in perfusion MRI parameters are
relevant in MS pathogenesis because they represent the
necessary step inducing a status defined as a hypoxia-
like condition [5].
It is possible that the presence and severity of venous
outflow blockages characterizing CCSVI may contribute
to reduced cerebral perfusion. In this study, we investi-
gated whether impaired venous outflow is related to
hypoperfusion of brain parenchyma.
Methods
Sixteen consecutive relapsing-remitting (RR) MS
patients and eight age- and sex-matched healthy con-
trols (HC) were enrolled in this study as previously
described [6]. Briefly, the inclusion criteria required
clinically definitive MS, RR MS disease course, an
Expanded Disability Status Scale (EDSS) score between
0 and 5.5, age 18 to 65 years, disease duration between
5 and 10 years, being treated with currently U.S. Food
and Drug Administration-approved, disease-modifying
treatments and having normal renal function (creatinine
clearance >58 ml/min). Exclusion criteria included an
acute relapse and/or steroid treatment within the 30
days preceding study entry, preexisting medical condi-
tions associated with brain pathology and abnormal
renal function.
All investigators conducting assessments were blinded
to the clinical, demographic, and subject group (MS or
HC) characteristics. We aimed to ensure proper blinding
by instructing subjects not to reveal their disease status
during the Doppler examination and including RR MS
patients with low disability or walking difficulties. The
Italian research group conducted the Doppler assess-
ment, and the Buffalo research group conducted clinical
and magnetic resonance imaging (MRI) examinations.
The clinical, Doppler and MRI assessments were con-
ducted on the same day for each subject.
The study was approved by the institutional review
board, and written informed consent was obtained from
all study subjects.
MRI scan acquisition and analysis
All subjects were examined on a 3-T GE Signa Excite
scanner (General Electric, Milwaukee, WI, USA). The
following sequences were acquired: two-dimensional (2-
D) multiplanar dual fast spin-echo proton density and
T2-weighted images, fluid-attenuated inversion recovery
(FLAIR) images, a 3-D high-resolution (HIRES) fast
spoiled gradient echo (FSPGR) with magnetization-pre-
pared inversion recovery (IR) pulse- and perfusion-
weighted imaging (PWI).
One average was used for all pulse sequences. With
the exception of PWI, all sequences were acquired with
a 256 × 192 matrix (frequency × phase) and field of
v i e w( F O V )o f2 5 . 6c m×1 9 . 2c m( 2 5 6×2 5 6m a t r i x
with phase FOV = 0.75) for an in-plane resolution of 1
mm × 1 mm. For all 2-D scans (PD/T2, FLAIR and SE
T1), 64 slices were collected with a thickness of 2 mm
and no gap between slices. For the 3-D HIRES IR-
FSPGR, 184 locations were acquired, 1 mm thick, pro-
viding for isotropic resolution. Other relevant para-
meters were as follows. For dual FSE PD/T2, echo and
repetition times (TE and TR) TE1/TE2/TR = 9/98/5300
ms; flip angle (FA) = 90; echo train length (ETL) = 14;
and acquisition time (AT) = 5:08 (min:sec). For FLAIR
images, TE/TI/TR = 120/2100/8500 ms (TI inversion
time), FA = 90, ETL = 24 and AT = 6:49. For SE T1-
W I ,T E / T R=1 6 / 6 0 0m s ,F A=9 0a n dA T=6 : 1 1 .F o r
3-D HIRES T1-WI, TE/TI/TR = 2.8/900/5.9 ms, FA =
10 and AT = 9:18.
Dynamic susceptibility contrast-enhanced PWIs were
acquired during and after injection of 15 ml of 0.1
mM/kg gadolinium-diethylenetriamine penta-acetic
acid with an MRI-compatible power injector at a speed
of 5 ml/s. The HC were also injected with the contrast
agent. Single-shot, gradient-echo, echo planar imaging
was used with the following parameters: TR 2275 ms,
TE 45 ms, FOV 26 × 26 cm, matrix 96 × 96 (resulting
in in-plane voxel sizes of 2.71 × 2.71 mm), 20 slices (7
mm thick) with no gap. Forty time points were
acquired per slice.
PWI characteristics of the gray matter (GM) and
white matter (WM) tissue compartments were assessed
by using SIENAX [7]. Subcortical gray matter (SGM)
structures were assessed by using FMRIB’sF I R S Ts o f t -
ware to segment high-resolution, 3-D, T1-weighted
images http://www.fmrib.ox.ac.uk/fsl/first/index.html
and included the thalamus, pulvinar nucleus of thala-
mus, caudate, putamen, globus pallidus, hippocampus,
amygdala, nucleus accumbens, red nucleus and substan-
tia nigra. Briefly, FIRST is a model-based segmentation/
registration program that uses shape/appearance models
constructed from manually segmented images. The
manual labels are parameterized as surface meshes and
modeled as a point distribution model. Deformable sur-
faces are used to automatically parameterize the volu-
metric labels in terms of meshes; the deformable
surfaces are constrained to preserve vertex correspon-
dence across the training data. Normalized intensities
along the surface normals are sampled and modeled.
The shape and appearance model is based on multivari-
ate Gaussian assumptions. Shape is then expressed as a
mean with modes of variation (principal components).
On the basis of the learned models, FIRST searches
through linear combinations of shape modes of variation
for the most probable shape instance, given the
observed intensities in the input image.
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cerebral blood volume (CBV) and mean transit time
(MTT) was conducted by blinded operators using a pre-
viously described method [8]. Briefly, we used the Java
Image Manipulation software package (Xinapse Systems,
Thorpe Waterville, UK) with an automated additive
interval-finding algorithm (searching 500 “artery-like”
candidate voxels and retaining the 40 best fitting voxels)
and singular value decomposition (cutoff at 20% of max-
imum singular value) for perfusion curve fitting [9]. CBF
and CBV values were relative, based on estimated tissue
relaxivity and hematocrit parameters (arterial relaxivity
1.0 L/s/M, tissue relaxivity 1.0 L/s/M, arterial hematocrit
0.45, tissue hematocrit 0.45). Correction for patient
motion prior to perfusion analysis was performed using
FMRIB’s Linear Image Registration Tool for Motion
Correction (MCFLIRT). Using the first steady-state
volume before contrast arrival time, we applied FMRIB’s
Linear Image Registration Tool (FLIRT) to derive an
affine transformation matrix, providing a transformation
from the native perfusion acquisition space to the high-
resolution FLAIR space. This matrix was then used to
coregister perfusion MTT, CBF and CBV maps into the
subject-specific upsampled FLAIR space. These maps
were then overlaid onto all relevant region-of-interest
masks to calculate mean values for MTT, CBF and CBV
within each tissue compartment (Figure 1).
Assessments of cerebral venous hemodynamics
Cerebral venous return was examined using echo-color
Doppler equipped with 2.5 and 7.5 to 10 MHz transdu-
cers (Esaote-Biosound My Lab 25, Genoa, Italy), with
the subject positioned on a bed tilted at 90° and 0° as
previously described [2].
All subjects were scanned in a blinded manner follow-
ing the established protocol for diagnosis of CCSVI [2],
consisting of transcranial and extracranial echo-color
Doppler to measure the following five venous hemody-
namic (VH) parameters indicative of CCSVI: (1) reflux
in the IJVs and/or in the vertebral veins (VVs) in sitting
and in supine positions (90° and 0°), with reflux defined
as flow directed toward the brain for a duration of >0.88
seconds; (2) reflux in the intracranial veins with reflux
defined as reverse flow for a duration of 0.5 seconds in
one of the insonated veins (superior and inferior petro-
sus sinus, and/or Rosenthal vein); (3) B-mode abnormal-
ities causing absence of flow or significant flow
disturbances (vestigial valves, septum, immobile valve
leaflets, see Figure 2), or stenoses in IJVs. IJV stenosis
was defined as a cross-sectional area of this vein ≤0.3
cm
2 ; (4) flow that is not Doppler-detectable in IJVs
and/or VVs despite multiple deep breaths; and (5) a
wider cross-sectional area of the IJVs in the upright
positions respect to supine. A subject was considered
CCSVI-positive if at least two VH criteria were fulfilled
as previously proposed [2].
We also calculated a VH insufficiency severity score
(VHISS), as previously described [6]. The VHISS is an
ordinal measure of the overall extent and number of
VH flow pattern anomalies, with a higher value of
VHISS indicating a greater severity of VH flow pattern
anomalies. For each of the five VH criteria, a “VHISS
contribution score” was assigned using the scheme
described below. These scores combined gave an overall
severity measure: the VHISS. The minimum possible
VHISS value is 0 and the maximum is 16.
As regards criterion VH1, there are eight venous seg-
ments that can potentially exhibit reflux in the two pos-
tures, and one point was assigned for each one at which
reflux was found to be present. Consequently, VH1 had
a VHISS contribution score that could range from a
minimum of 0 to a maximum of 8.
Figure 1 Representative source and processed images used for
perfusion calculations. (a) Original fluid-attenuated inversion
recovery images. (b) Gray, white and deep gray structure
segmentations: gray matter in medium gray, white matter in light
gray, thalamus in green, globus pallidus in dark blue, putamen in
magenta, caudate in light blue and nucleus accumbens in orange.
(c) Cerebral blood flow (CBF) map: low flow in red and high flow in
green. (d) Cerebral blood volume map: low volume in red and high
volume in green. (e) Mean transit time map: short transit time in
green and long transit time in red.
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of 1 if reflux was present in the intracranial veins in only
one posture and a VHISS contribution score of 2 if it was
present in both postures. The VHISS contribution score
for this criterion was additionally weighted with a factor of
2 if reflux toward the subcortical GM could be detected.
Consequently, the VHISS contribution score for VH2
could range from a minimum of 0 to a maximum of 4.
The VHISS contribution score for VH3 ranged from 0
to 2, depending on whether B-mode anomalies disturb-
ing outflow were present in none, one or both of the
IJVs, respectively (Figure 1). VH3 was assigned a contri-
bution score of 0 if either VH1 or VH4 was positive for
t h ep r e s e n c ei ne i t h e rp o s t u re of reflux or obstruction
in the IJV of interest.
The scoring scheme for the contribution of VH4 to
the VHISS was the same as that for VH1, with the dif-
ference being that only blocks were considered. No
points were assigned for segments and postures in
which reflux had previously been detected under VH1.
The VH5 criterion had an overall VHISS contribution
score between 0 and 4, calculated by assigning 0 to 2
points for each IJV. A -ΔCSA value was assigned a
score of 2, whereas a ΔCSA value <7 mm
2, correspond-
ing to the 25th percentile of ΔCSA distribution in
healthy controls, was assigned a score of 1. ΔCSA >7
mm
2 was assigned a score of 0.
The overall VHISS score was defined as a weighted
sum of the scores contributed by each individual abnor-
mal venous haemodynamics (A-VH) criterion. The for-
mula for VHISS calculations was as follows:
VHISS =++++ VHISS VHISS VHISS VHISS VHISS 12345
T h es u b s c r i p t si nt h i sf o r m u l ai n d i c a t et h es u b s c o r e s
for the five VH criteria.
Statistical analysis
Statistical analysis was performed using the SPSS version
1 6 . 0( S P S S ,I n c . ,C h i c a g o ,I L ,U S A ) .T h ea g e sa n dp r o -
portions of females and males in the MS and HC groups
were assessed with the Student’s t-test and Fisher’s exact
test, respectively. The nonparametric Mann-Whitney U
test was used to assess the VHd i f f e r e n c e sb e t w e e nt h e
MS and HC groups. Spearman correlation analysis was
used to assess the relationship between PWI measures
and the severity of CCSVI.
Since this was a preliminary exploratory study, we
used a false discovery rate (FDR) correction [10] rather
than a family-wise error rate (FWER) correction to cor-
rect for multiple comparisons on our outcome mea-
sures. FDR provides a statistical bound on the total
percentage of incorrectly rejected null hypotheses rather
than on the probability of any error occurring and is
therefore considerably more powerful while still provid-
ing strong control. For the current work, we used an
FDR threshold of 0.05, so we expect a 5% error rate for
findings we consider significant. In the results, we report
both uncorrected (P) and FDR-corrected (Q) statistics.
Results
The demographic, clinical and VH characteristics of MS
patients and HC groups are summarized in Table 1.
Figure 2 Ultrasound assessment in CCSVI. (a) Triplex scanner, longitudinal access of the neck in chronic cerebrospinal venous insufficiency
multiple sclerosis patient. In the distal internal jugular vein, close to the junction, the flow is blocked as demonstrated both by the absence of
color and by the Doppler spectrum analysis, with the sample completely open in the lumen and no angle correction. (b) An immobile
intraluminal defect of the defined septum (multiple arrows) almost completely obstructing the lumen shows the cause of the hampered venous
outflow.
Zamboni et al. BMC Medicine 2011, 9:22
http://www.biomedcentral.com/1741-7015/9/22
Page 4 of 9The proportion of females to males (P =0 . 6 7 ,F i s h e r ’s
exact test) and the mean age of the two groups (P =
0.37) were similar. All MS patients were on disease-
modifying therapy (seven were on subcutaneous inter-
feron-b1a, two were on intramuscular interferon-b1a,
four were on natalizumab and three were on glatiramer
acetate).
All 16 MS patients fulfilled the diagnosis of CCSVI
(median VH = 4 and median VHISS = 9) and none of
t h eH C( T a b l e1 )( P <0 . 0 0 1 ,F i s h e r ’s exact test). This
means a CCSVI prevalence in this small group of MS
patients of 100%, with prevalence of 0% in HC. The two
venous scales, VHISS and number of VH criteria ful-
filled, were significantly correlated with CCSVI diagnosis
(r = 0.84 for VHISS, r = 0.84 for VH; P < 0.001 for both
scales). Therefore, to decrease the number of compari-
sons, we used only VHISS for further analyses with PWI
outcomes.
There was a significant association between increased
VHISS and decreased CBF in the majority of examined
regions of the brain parenchyma in MS patients (Figures
3 to 5 and Table 2). The most robust correlations were
observed for GM (Figure 3) and WM (Figure 4) (r =
-0.70 to -0.71, P < 0.002, Q = 0.022) and for the puta-
men, thalamus, pulvinar nucleus of thalamus, globus
pallidus and hippocampus (r = -0.59 to -0.71, P <0 . 0 1 ,
Q < 0.05). No results for correlation between VHISS
and CBV or MTT survived multiple comparison correc-
tion (Figures 3 and 4 and Table 2). No significant rela-
tionship was observed between VHISS and PWI
outcomes in HC.
Discussion
This pilot study demonstrates that the presence and
severity of CCSVI are associated with hypoperfusion of
the brain parenchyma in patients with MS. In particular,
a strong relationship was found between increased
VHISS and decreased CBF in the GM, SGM and WM
regions of the brain. No significant association was
found in HC.
It has previously been demonstrated that MS patients
show abnormal blood flow PWI patterns. These include
increased MTT and decreased CBF and CBV within nor-
mal appearing WM and GM [4,11-15]. Perfusion
abnormalities in the normal appearing WM are present
from the earliest stages of the disease. The GM perfusion
changes seem to appear somewhat later in the disease
[4,13] and involve the thalamus, putamen and other
SGM structures. PWI indices are also altered in both
enhancing and nonenhancing lesions [12]. The severity
of the perfusion changes is more pronounced in progres-
sive MS compared to relapsing forms of the disease
[11,13,15]. The hemodynamic abnormalities detected on
PWI in patients with MS are currently interpreted as
being a consequence of chronic inflammatory events
related to local blood congestion and secondary hypere-
mia of the brain parenchyma [11,13,15]. Furthermore, at
this time, it is not clear whether reduced perfusion of the
WM and GM in MS patients is a sign of vascular pathol-
ogy or decreased metabolic demand [5]. Alternatively, it
can be hypothesized as the presence of a disorder that
involves the major vasoactive substances. Norepinephr-
ine, endothelin-1 and angiotensin II have been measured
Table 1 Demographic, clinical and venous hemodynamic characteristics of relapsing remitting MS patients and
healthy controls
a
Characteristic MS patients
(n = 16)
Healthy controls
(n =8 )
P value
Female sex, n (%) 10 (63%) 6 (75%) NS
Mean age, yr (±SD) 36.1 ± 7.3 33.1 ± 7.3 NS
Disease duration, mean (±SD) 7.5 ± 1.9
Age at diagnosis, mean (±SD) 35.8 ± 9.2
Expanded Disability Status Scale, mean (±SD) and median (range) 2.4 ± 0.9, 2.5 (1.0 to 3.5)
Mean Multiple Sclerosis Functional Composite score (±SD) -2.5 ± 0.03 -2.5 ± 0.02 NS
Mean treatment duration, yr (±SD) 4.3 ± 3.4
Distribution of VH criteria, n (%)
VH1 12 (75%) 0 (0%) <0.001
VH2 14 (88%) 0 (0%)
VH3 14 (88%) 1 (13%)
VH4 13 (81%) 0 (0%)
VH5 8 (50%) 0 (0%)
Mean number of VH criteria (±SD) 3.8 ± 0.23 0.12 ± 0.35 <0.001
Mean VHISS (±SD) 8.9 ± 2.8 0 ± 0 <0.001
aMS, multiple sclerosis; VH, venous hemodynamic; SD, standard deviation; VHISS, venous hemodynamic insufficiency severity score; NS, nonsignificant. The
differences between MS patients and healthy controls were assessed using the Student’s t-test, Fisher’s exact test and Mann-Whitney rank-sum test.
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of the limbs, but not yet in CCSVI or in MS [16].
Although hypoperfusion is consistently present in MS
lesions and GM and WM, the formation of new lesions is
preceded by hyperperfusion changes [17]. Increased per-
f u s i o ni nt h ea r e ao fl e s i o nf o r m a t i o nc o u l db eas i g no f
vessel dilation mediated by proinflammatory cytokines.
An altered CBF pattern may be a consequence not
only of local circulatory disturbances due to inflamma-
tory mechanisms in acute or chronic phases, but instead
could result from an outflow blockage situated far away
f r o mt h el e s i o n s .C C S V Ii sav a s c u l a rc o n d i t i o n
described in MS patients that is characterized by ste-
noses caused by intraluminal defects such as web, sep-
tum, malformed valve or, rarely, by segmental
hypoplasia/agenesis [1,2]. Stenosing lesions of CCSVI
have been classified among the truncular venous malfor-
mation in a consensus document [18,19].
Therefore, CCSVI may impact local hemodynamics
and overload microcirculation at places distant from
the location of the mechanical stenosis, as in any con-
dition of venous obstruction of the major trunks.
Such a mechanism may lead to capillary hypertension
and leakage, consistently contributing to inflammation
[20]. In this pilot study, we have shown a strong rela-
tionship between the severity of CCSVI and hypoper-
fusion in the WM, GM and SGM. There are other
examples of overload of the cerebral venous circula-
tion, albeit triggered by different mechanisms from
those of CCSVI, leading to hemodynamic abnormal-
ities similar to those reported in this study. For exam-
ple, the picture of dural arteriovenous fistula,
characterized by plaques very similar to those of MS
as well as by retrograde cortical venous drainage,
shows abnormal perfusion parameters of CBV, CBF
and MTT [21,22].
While we believe the present study provides important
information about a poorly understood aspect of MS
characteristics, it does have a number of limitations that
motivate further work. First, the use of an FDR correc-
tion approach provides confidence in the overall body of
results presented, but indicates that we expect approxi-
mately 5% of them to be incorrect. Thus, we can be
confident that there is an overall relationship between
VHISS and CBF in various areas of the brain, but need
to further confirm individual regional findings in a more
Figure 3 Scatterplots showing the relationship between venous hemodynamic insufficiency severity score and gray matter mean
transit time (left), cerebral blood flow (center) and cerebral blood volume (right) tissue perfusion parameters in patients with
relapsing-remitting multiple sclerosis.
Figure 4 Scatterplots showing the relationship between venous hemodynamic insufficiency severity score and white matter mean
transit time (left), cerebral blood flow (center) and cerebral blood volume (right) tissue perfusion parameters in patients with
relapsing-remitting multiple sclerosis.
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interpreting our perfusion results, it should be consid-
ered that absolute quantitation of CBF and CBV is chal-
lenging on dynamic contrast enhanced MRI. Some key
parameters are estimated here and may not be correct.
Nonetheless, the same MRI sequence, postprocessing
steps and algorithm parameters were used for all sub-
jects in all groups, so relative comparisons and correla-
tions should still be reliable. Finally, several studies have
reported that hypoperfusion of the brain parenchyma in
MS patients advances with disease progression. It can-
not be excluded that venous anomalies (CCSVI) may be
secondary to reduced perfusion or that both are simply
correlated with no direct causative relationship. Even if
there were a causative relationship, the strongest r value
we saw was 0.72, corresponding to a model explaining
only about 50% of the overall variance seen. Thus, there
may be other factors at work, and/or our measures may
not be completely adequate to characterize individual
hemodynamics. In either case, although we have estab-
lished a relationship between CCSVI and reduced brain
perfusion, the exact nature of that relationship remains
uncertain and should be further investigated.
Several recent reports have presented evidence against
the CCSVI hypothesis [23-25]. Particularly, a study of 56
MS patients and 20 HC found no differences in cere-
brospinal venous drainage using transcranial and extra-
cranial Doppler imaging. However, in this study, there
were significant deviations from the original Doppler
methodology adopted in previous and in the present
Figure 5 Perfusion MRI study. Left: Cerebral blood flow (CBF) in a 33-year-old, relapsing-remitting (RR) chronic cerebrospinal venous
insufficiency (CCSVI) multiple sclerosis (MS) patient with a venous hemodynamic insufficiency severity score (VHISS) of 5. Right: CBF in a 38-year-
old, RR CCSVI-MS patient with a VHISS of 12. The dark areas indicate lower CBF in the patient with higher VHISS.
Table 2 Spearman correlation coefficients, P values, and false discovery rate-corrected Q values between venous
hemodynamic insufficiency severity score and perfusion-weighted measures in relapsing-remitting patients
Mean transit time,
r, P/Q
Cerebral blood flow,
r, P/Q
Cerebral blood volume,
r, P/Q
Gray matter 0.52,
a 0.039/0.100
a -0.70,
b 0.002/0.022
b -0.58,
a 0.019/0.062
a
White matter 0.53,
a 0.034/0.094
a -0.71,
b 0.002/0.022
b -0.49, 0.054/0.110
Caudate 0.50,
a 0.049/0.110
a -0.38, 0.142/0.189 -0.30, 0.266/0.319
Putamen 0.47, 0.065/0.117 -0.72,
b 0.002/0.022
b -0.42, 0.107/0.161
Globus pallidus 0.44, 0.087/0.142 -0.69,
b 0.003/0.022
b -0.22, 0.404/0.428
Thalamus 0.46, 0.074/0.127 -0.65,
b 0.007/0.042
b -0.62,
a 0.011/0.052
a
Pulvinar thalamus 0.25, 0.342/0.385 -0.67,
b 0.003/0.022
b -0.50, 0.051/0.110
Hippocampus 0.34, 0.201/0.250 -0.61,
a 0.012/0.052
a -0.41, 0.117/0.162
Amygdala 0.14, 0.604/0.604 -0.4, 0.091/0.142 -0.47, 0.064/0.117
Nucleus accumbens 0.49, 0.055/0.110 -0.60
a 0.015/0.054
a -0.26, 0.336/0.384
Red nucleus 0.37, 0.163/0.210 -0.56,
b 0.025/0.075
b -0.41, 0.112/0.161
Substantia nigra 0.17, 0.539/0.554 -0.60,
a 0.013/0.052
a -0.23, 0.394/0.428
aFindings significant without false discovery rate (FDR) correction;
bsignificant correlations and findings surviving FDR correction.
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study and other studies emphasize the need for a multi-
modal approach for the assessment of CCSVI.
Finally, accumulating evidence suggests that the
increased energy demand of impulse conduction along
excitable demyelinated axons and reduced axonal ATP
production induce a chronic state of virtual hypoxia in
demyelinated axons [27-29]. In response to such a state,
further hypoperfusion of brain parenchima, facilitated by
venous outflow disturbances, may contribute to chronic
necrosis of axons and mitochondrial dysfunction.
Conclusions
To the best of our knowledge, this pilot study is the first
to report a significant relationship between the presence
and severity of CCSVI and hypoperfusion in the brain
parenchyma. These preliminary findings should be con-
firmed in a larger cohort of MS patients to ensure that
they generalize to the MS population as a whole.
Reduced perfusion could contribute to the known
mechanisms of virtual hypoxia in degenerated axons.
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